| Literature DB >> 34739982 |
Yanzhi Liu1, Liuqi Peng2, Lingli Li3, Cuishan Huang3, Keda Shi3, Xiangbo Meng3, Pinpin Wang2, Mingming Wu2, Ling Li3, Huijuan Cao3, Kefeng Wu4, Qingqiang Zeng3, Haobo Pan2, William Weijia Lu5, Ling Qin6, Changshun Ruan7, Xinluan Wang8.
Abstract
Osteochondral defect repair in osteoarthritis (OA) remains an unsolved clinical problem due to the lack of enough seed cells in the defect and chronic inflammation in the joint. To address this clinical need, we designed a bone marrow-derived mesenchymal stem cell (BMSC)-laden 3D-bioprinted multilayer scaffold with methacrylated hyaluronic acid (MeHA)/polycaprolactone incorporating kartogenin and β-TCP for osteochondral defect repair within each region. BMSC-laden MeHA was designed to actively introduce BMSCs in situ, and diclofenac sodium (DC)-incorporated matrix metalloproteinase-sensitive peptide-modified MeHA was induced on the BMSC-laden scaffold as an anti-inflammatory strategy. BMSCs in the scaffolds survived, proliferated, and produced large amounts of cartilage-specific extracellular matrix in vitro. The effect of BMSC-laden scaffolds on osteochondral defect repair was investigated in an animal model of medial meniscectomy-induced OA. BMSC-laden scaffolds facilitated chondrogenesis by promoting collagen II and suppressed interleukin 1β in osteochondral defects of the femoral trochlea. Congruently, BMSC-laden scaffolds significantly improved joint function of the injured leg with respect to the ground support force, paw grip force, and walk gait parameters. Therefore, this research demonstrates the potential of 3D-bioprinted BMSC-laden scaffolds to simultaneously inhibit joint inflammation and promote cartilage defect repair in OA joints.Entities:
Keywords: 3D bioprinting; BMSC-Laden scaffolds; Cartilage defect; Osteoarthritis; Osteochondral regeneration
Mesh:
Substances:
Year: 2021 PMID: 34739982 DOI: 10.1016/j.biomaterials.2021.121216
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479